Showing 5441-5450 of 6036 results for "".
- Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Projecthttps://modernod.com/news/acucela-meets-with-nasa-and-trish-for-phase-1-update-for-ss-oct-project/2477272/Acucela announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health (TRISH)1 to present the status of its Swept Source-OCT (SS-OCT) device being developed for NASA’s Deep Space missions. The purpose of the meeting, which too
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Potent affronEYE Saffron Extract May Lower Risk of Glaucomahttps://modernod.com/news/potent-affroneye-saffron-extract-may-lower-risk-of-glaucoma/2477259/A new animal study suggests affronEYE saffron could help prevent the onset of glaucoma. The antioxidant and anti-inflammatory characteristics of this potent saffron extract, developed by Pharmactive Biotech Products, S.L., demonstrated an ability to protect retinal cells from damage and death and
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to
- Clearwave Launches New Patient Interface Solutionhttps://modernod.com/news/clearwave-launches-new-patient-interface-solution/2477249/Clearwave, a provider of patient check-in solutions via mobile, kiosk, and desktop, announced the launch of Clearwave Connect, a new tablet-based application to enhance front-office experiences. With Clearwave Connect, practices will have the ability to improve check-in speed and accessibility wi
- Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma’s Impact on Daily Livinghttps://modernod.com/news/allergan-teams-up-with-super-bowl-mvp-von-miller-to-raise-awareness-of-glaucomas-impact-on-daily-living/2477236/Allergan announced a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker, and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the ‘My Glaucoma’ campaign, Mr. Miller wil
- Bionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye Systemhttps://modernod.com/news/bionic-vision-technologies-announces-interim-pilot-study-results-of-the-bvt-bionic-eye-system/2477228/Bionic Vision Technologies announced interim results of a pilot study involving 4 patients with late-stage retinitis pigmentosa (RP) implanted with a visual prosthesis designed to improve awareness of external objects
- Aura Biosciences Appoints George Golumbeski, PhD, as Chairman of the Board of Directorshttps://modernod.com/news/aura-biosciences-appoints-george-golumbeski-phd-as-chairman-of-the-board-of-directors/2477212/Aura Biosciences announced the appointment of George Golumbeski, PhD, as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry. “George’s extensive experience will be invaluable to Aura as we